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low-up was 14.6 months. The HeRO patients under-
went a mean of 6.4 previous TDCs and 3.1 previous
AVG/AVFs. The LEAVG patients underwent a mean of
4.1 previous TDCs and 2.8 previous AVG/AVFs. The
principal difference was a 1 year primary patency of 26%
for the HeRO group and 60% for the LEAVG group
(P  .01). The number of interventions to maintain
patency was 6.2 per year in the HeRO group and 3.7 per
year in the AVG group (P  .40). Secondary patency at
1 year was 61% for the HeRO patients and 66% for the
AVG patients (P  .56). The HeRO group and LEAVG
had no difference in infection rate (31% vs. 30%) or
mortality rate (33% vs 21% respectively) at 1 year.
Conclusions: In access challenged patients, LEAVG
and HeRO offer a higher incidence of infection, mortality
and loss of patency compared to traditional upper extremity
access. The LEAVG offers improved primary patency rate
over the HeRO device.
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Video Presentation
Percutaneous Thrombectomy of a Dialysis Graft in the
Office Setting
Krishna Jain1, John Munn2, Mark Rummel2, Dan John-
ston2, Chris Longton2. 1Advanced Vacular Surgery, Kala-
mazoo, MI; 2Advanced Vascular Surgery, Kalamazoo, MI
Background: With the advent of endovascular techniques
thrombectomy of occluded dialysis graft can be carried out per-
cutaneously. Over the last few years various devices have been
approved for mechanical thrombectomy of dialysis graft. We
describe a technique thatwehave developedwithout using these
devices, in our office based endovascular suite.
Technical Description: Patient is given hydrocodone 5
mg, Diazepam 5 mg and Cefazolin 500 mg orally before the
procedure. Patient is not fasting. After prepping and draping
the extremity Xylocaine 1% is infiltrated in the skin. Crossing
micro puncture needles are introduced into the graft pointing
towards each anastomosis. Guide wires are threaded through
the needles. Needles are removed andmicro puncture sheaths
are threaded over the guide wires. Fistulogram is done to
confirm the thrombosis and to make sure the catheters are in
the lumen. Two ml of tissue plasminogen activator is intro-
duced through each catheter. After 15minutes glide wires are
threaded through each sheath and these are switched to 6
French sheaths. The glidewires should cross both anastomo-
ses. Five French embolectomy catheter is threaded over the
arterial wire and clot is pulled out of the arterial side and
flushed out of the side port of the sheath. Same procedure is
carried out on venous side. Fistulogram is performed and the
procedure is repeated until there is no residual clot. Invariably
there is stenosis present at the graft vein anastomosis or in the
graft circuit. Rarely there is arterial stenosis. If it is a 6mm graft
8mmballoon is used todilate the area of stenosis at the graft vein
anastomosis. The sheaths and guide wires are removed and
puncture sites are closedwith nylon suture. the graft can be used
immediately. A similar procedure can be used for a fistula.
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Hemodialysis A and Age-Related Postoperative Out-
comes: Which Fistula First?
Steven Abramowitz, Angela A. Kokkosis, Jonathan Schwit-
zer, Harry Schanzer, Victoria Teodorescu. Mount Sinai
Medical Center, New York, NY
Objectives: The National Kidney Foundation recom-
mends the preferential creation of radiocephalic fistulas
(RCF) over that of brachiocephalic fistulas (BCF) for he-
modialysis access. This study tested the hypothesis that
RCF creation in patients greater than 68 years of age may
result in a more postoperative complications.
Methods:A total of 287patients older than68 years of age
with preoperative vein mapping and regular follow up after cre-
ation of arteriovenous fistula constituted this retrospective study.
Within this group, 164 patients underwent RCF creation and
123underwentBCFcreation.Medical recordswere analyzed for
thenumberof central venous catheter days, thenumberof fistula
related procedures recorded and the number of access related
hospitalizations for each patient. Bivariate analysis using linear
modeling and one-way analysis of variance was used to assess
cohort differences.
Results: Among patients who underwent creation of
BCF, the average number of central venous catheter days was
53.3 days per patient, the average number of fistula related
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procedures recorded was 0.6 per patient and the number of
hemodialysis related hospitalizations was 0.3 per patient.
Among patients who underwent creation of RCF, the average
number of central venous catheter days was 83.4 days per
patient, the average number of fistula related procedures re-
corded was 1.8 per patient and the average number of hemo-
dialysis related hospitalizations was 0.8 per patient. There was
a statistically significant difference postoperative course be-
tween those patients who underwent BCF versus RCF
creation.
Conclusions: Patients greater than 68 years of age who
undergoRCFcreationmayhave agreater likelihoodof increased
central venous catheterdays, a greaternumberofhospitalizations
related to hemodialysis access and a greater number of postoper-
ative procedures than those who undergo BCF creation.
Author Disclosures: S. Abramowitz: Nothing to dis-
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C9a: Poster Session - Aortic Disease (1)
PS2.
Fenestrated/Branched Endovascular Aortic Repair
(FEVAR) for Chronic Type B Aortic Dissection with
Thoracoabdominal Aneurysms (TAAA)
Atsushi Kitagawa1, Roy K. Greenberg1, Matthew J. Eagle-
ton1, Tara M. Mastracci1, Eric Roselli2. 1Cleveland Clinic
Department of Vascular Surgery, Cleveland, OH; 2Cleveland
Clinic Department of Thoracic Surgery, Cleveland, OH
Objectives: Treatment of patients with arch, TAAA
and chronic dissection is challenging.We report the results
of FEVAR of such aneurysms.
Methods: A single center prospective FEVAR trial
enrolled 356 patients(2006-11), of which 29 had chronic
dissections with arch and/or TAAA. Patients were divided
into a group with extensive dissections from the arch
through the visceral segment(Group A, n  15, mean age
57y), and a group with focal dissections(Group B, n  14,
mean age 73y).Customized grafts were implanted into the
true lumen, from which all supra-aortic trunk(arch branch
devices) and visceral vessels were supplied.Patients were
followed annually with imaging and laboratory studie-
s.Outcome analyses included survival, rupture, spinal cord
ischemia, endoleak, morbidity(cardiac, renal, pulmonary),
secondary interventions, dissection and aneurysm growth.
Results: Mean time between dissection and FEVAR
was 10.6 years, and aneurysm size was 61mm. Follow-up
averaged 1.7 years. There were no perioperativemortalities,
and one aortic related death at 90 days due to progression
of pre-existing untreated arch dissection. No ruptures,
cardiac, renal, paraplegia or pulmonary complications oc-
curred. Despite narrow true lumen dimensions, stentgrafts
expanded to their nominal diameters in all cases without
graft compression. Post FEVAR growth was noted in
two cases (one Marfan/one LDS), related to type II
endoleaks. Sac regression was similar (7.5mm vs
10.1mm). Early secondary interventions were more
common in group A, occurring in 7 patients (all endo-
vascular). Younger patients, and those with a defined
connective tissue disease (Marfans/LDS) were more
commonly in Group A (P.001).
Conclusions: FEVAR is feasible for patients with
chronic dissections with arch and TAAA.Visceral vessel
access and graft compression resulting from narrow true
lumen diameters were not problems in this select popula-
tion.Favorable sac and lumen morphologic changes cou-
pled with lowmortality and complication risk makes this an
attractive treatment option.
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Biomechanical Rupture Risk Assessment of AAA Made
Easier for Clinicians
Joy Roy1, Jesper Swedenborg1, Natzi Sakalihasan2, Alain
Nchimi2, Dittmar Bockler3, Alexander Hyhlik-Durr3,
Christian Gasser4. 1Dept of Vascular Surgery, Karolinska
Hospital/Institute, Stockholm, Sweden; 2University Hos-
pital of Liege, Liege, Belgium; 3University of Heidelberg,
Heidelberg, Germany; 4Royal Institute of Technology,
Stockholm, Sweden
Objectives: Finite Element (FE) Analysis has been used
to estimate peak wall stress(PWS) and peak wall rupture
risk(PWRR) of Abdominal Aortic Aneurysms(AAA).
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